Continuous Subcutaneous XXXX Infusion in Italy: Third National Survey.

@entity1 @entity2690 @entity413 @entity6
UNASSIGNED: Background: Continuous subcutaneous @entity2690 infusion (CSII) is increasing worldwide, mostly because of improved technology. The aim of this study was to evaluate the current status of CSII in Italy. Materials and Methods: Physicians from 272 @entity6 centers received a questionnaire investigating clinical features, pump technology, and management of @entity1 on CSII. Results: Two hundred seventeen centers (79.8%) joined the study and, by the end of April 2013, gave information about 10,152 @entity1 treated with CSII: 98.2% with @entity6 , 81.4% adults, 57% female, and 61% with a conventional pump versus 39% with a sensor-augmented pump. CSII advanced functions were used by 68% of @entity1 , and @entity413 sensors were used 12 days per month on average. Fifty-eight percent of @entity6 centers had more than 20 @entity1 on CSII, but there were differences among centers and among regions. The main indication for CSII was poor @entity413 control. Dropout was mainly due to pump wearability or nonoptimal glycemic control. Twenty-four hour assistance was guaranteed in 81% of centers. A full @entity6 team (physician+nurse+dietician+psychologist) was available in 23% of adult-care @entity6 centers and in 53% of pediatric @entity6 units. Conclusions: CSII keeps increasing in Italy. More work is needed to ensure uniform treatment strategies throughout the country and to improve pump use.
